Presentation is loading. Please wait.

Presentation is loading. Please wait.

Associations of VO2peak to significant predictors.

Published byCéline Faubert Modified over 5 years ago

Similar presentations

Presentation on theme: "Associations of VO2peak to significant predictors."— Presentation transcript:

1 Associations of VO2peak to significant predictors.
Associations of VO2peak to significant predictors. Influence of age (A), body mass index (BMI) (B), systolic blood pressure (SBP) (C), resting heart rate (RHR) (D), physical activity index (E) and patient global assessment (PGA) (F) on VO2peak, based on the multivariable model including age, gender, BMI, RHR, smoking, SBP, physical activity index and PGA. Circles: women; diamonds: men; grey areas: 95% CIs. Marthe Halsan Liff et al. RMD Open 2019;5:e000912 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Associations of VO2peak to significant predictors."

Similar presentations

Lacto-ovo vegetarian group

Lacto-ovo vegetarian group
Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,
Multivariable model of abatacept retention in biologic-naïve patients.

Multivariable model of abatacept retention in biologic-naïve patients.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.

Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
Univariate predictors of (A) ASDAS ID (<1

Univariate predictors of (A) ASDAS ID (<1
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Similar presentations

Ads by Google